Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ALOX5AP is a new prognostic indicator in acute myeloid leukemia. | Discov Oncol | 2023 | 37994961 | PubTator, text mining | PubMed |
| Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. | Cell Rep Med | 2023 | 37992684 | PubTator, text mining | PubMed |
| Long non-coding RNAs emerge as a novel prognostic indicator in pediatric acute myeloid leukemia. | Transl Pediatr | 2023 | 37969114 | PubTator, text mining | PubMed |
| Ex Vivo Anti-Leukemic Effect of Exosome-like Grapefruit-Derived Nanovesicles from Organic Farming-The Potential Role of Ascorbic Acid. | Int J Mol Sci | 2023 | 37958646 | PubTator, text mining | PubMed |
| Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study. | Blood Cancer J | 2023 | 37957175 | PubTator, text mining | PubMed |
| Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia. | Front Pharmacol | 2023 | 37954840 | PubTator, text mining | PubMed |
| The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging 'nonmutational epigenetic reprogramming' cancer hallmark. | Comput Struct Biotechnol J | 2023 | 37954147 | PubTator, text mining | PubMed |
| From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis. | Hemasphere | 2023 | 37953829 | PubTator, text mining | PubMed |
| A scoring system based on fusion genes to predict treatment outcomes of the non-acute promyelocytic leukemia pediatric acute myeloid leukemia. | Front Med (Lausanne) | 2023 | 37942413 | PubTator, text mining | PubMed |
| Comprehensive pan-cancer investigation: unraveling the oncogenic, prognostic, and immunological significance of Abelson interactor family member 3 gene in human malignancies. | Front Mol Biosci | 2023 | 37942289 | PubTator, text mining | PubMed |
| Features of the TCR repertoire associate with patients' clinical and molecular characteristics in acute myeloid leukemia. | Front Immunol | 2023 | 37928542 | PubTator, text mining | PubMed |
| Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation. | Front Immunol | 2023 | 37928518 | PubTator, text mining | PubMed |
| Germline and somatic drivers in inherited hematologic malignancies. | Front Oncol | 2023 | 37904876 | PubTator, text mining | PubMed |
| AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects. | Cell Death Discov | 2023 | 37903788 | PubTator, text mining | PubMed |
| Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts. | Int J Mol Sci | 2023 | 37894806 | PubTator, text mining | PubMed |
Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year. | Cancers (Basel) | 2023 | 37894431 | PubTator, text mining | PubMed |
| A Review of FLT3 Kinase Inhibitors in AML. | J Clin Med | 2023 | 37892567 | PubTator, text mining | PubMed |
| SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML. | Oncogene | 2023 | 37891368 | PubTator, text mining | PubMed |
| Protein-Nanocaged Selenium Induces t(8;21) Leukemia Cell Differentiation via Epigenetic Regulation. | Adv Sci (Weinh) | 2023 | 37888866 | PubTator, text mining | PubMed |
| Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma. | J Pers Med | 2023 | 37888109 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=10